XML 27 R16.htm IDEA: XBRL DOCUMENT

Grant Revenues	12 Months Ended
Dec. 31, 2019
Grant Revenues [Abstract]
Grant Revenues	9. Grant Revenues In June 2015, the Company entered into a Cancer Research Grant Contract (“Grant Contract”) with CPRIT, under which CPRIT awarded a grant not to exceed $19.8 million for use in developing cancer treatments by exploiting the metabolism of cancer cells. The Grant Contract covered a four-year period from June 1, 2014 through May 31, 2018. Upon commercialization of the product, the terms of the Grant Contract require the Company to pay tiered royalties in the low to mid-single digit percentages. Such royalties reduce to less than one percent after a mid-single-digit multiple of the grant funds have been paid to CPRIT as royalties. The contract ended in May 2018 with the full $19.8 million grant recognized as revenue over the life of the award. For the year ended December 31, 2019, the Company recognized no grant revenue. For the years ended December 31, 2018 and 2017, the Company recognized $3.9 million, and $5.2 million, respectively, in grant revenues for qualified expenditures under the grant. As of December 31, 2018, all grant proceeds had been collected.

Grant Revenues

12 Months Ended

Dec. 31, 2019

9. Grant Revenues

In June 2015, the Company entered into a Cancer Research Grant Contract (“Grant Contract”) with CPRIT, under which CPRIT awarded a grant not to exceed $19.8 million for use in developing cancer treatments by exploiting the metabolism of cancer cells. The Grant Contract covered a four-year period from June 1, 2014 through May 31, 2018.

Upon commercialization of the product, the terms of the Grant Contract require the Company to pay tiered royalties in the low to mid-single digit percentages. Such royalties reduce to less than one percent after a mid-single-digit multiple of the grant funds have been paid to CPRIT as royalties.

The contract ended in May 2018 with the full $19.8 million grant recognized as revenue over the life of the award. For the year ended December 31, 2019, the Company recognized no grant revenue. For the years ended December 31, 2018 and 2017, the Company recognized $3.9 million, and $5.2 million, respectively, in grant revenues for qualified expenditures under the grant. As of December 31, 2018, all grant proceeds had been collected.